

David Crosiers

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6167087/david-crosiers-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

34
papers

1,315
citations

17
h-index

36
g-index

39
ext. papers

1,557
ext. citations

5.3
avg, IF

3.46
L-index

#	Paper	IF	Citations
34	A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. <i>JAMA Neurology</i> , 2013 , 70, 727-35	17.2	285
33	Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. <i>Lancet Neurology</i> , 2011 , 10, 898-908	24.1	237
32	Large-scale replication and heterogeneity in Parkinson disease genetic loci. <i>Neurology</i> , 2012 , 79, 659-67	6.5	106
31	A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. <i>Journal of Medical Genetics</i> , 2012 , 49, 721-6	5.8	78
30	DLB and PDD: a role for mutations in dementia and Parkinson disease genes?. <i>Neurobiology of Aging</i> , 2012 , 33, 629.e5-629.e18	5.6	52
29	Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population. <i>Human Mutation</i> , 2009 , 30, 1054-61	4.7	52
28	Parkinson disease: insights in clinical, genetic and pathological features of monogenic disease subtypes. <i>Journal of Chemical Neuroanatomy</i> , 2011 , 42, 131-41	3.2	51
27	Mindfulness Training among Individuals with Parkinson's Disease: Neurobehavioral Effects. <i>Parkinson's Disease</i> , 2015 , 2015, 816404	2.6	49
26	Global investigation and meta-analysis of the C9orf72 (G4C2) _n repeat in Parkinson disease. <i>Neurology</i> , 2014 , 83, 1906-13	6.5	49
25	Juvenile dystonia-parkinsonism and dementia caused by a novel ATP13A2 frameshift mutation. <i>Parkinsonism and Related Disorders</i> , 2011 , 17, 135-8	3.6	48
24	A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease. <i>Neurobiology of Aging</i> , 2011 , 32, 548.e9-18	5.6	46
23	Myoclonus and cerebellar ataxia following Coronavirus Disease 2019 (COVID-19). <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 974	2.2	30
22	Mutated ATP10B increases Parkinson's disease risk by compromising lysosomal glucosylceramide export. <i>Acta Neuropathologica</i> , 2020 , 139, 1001-1024	14.3	27
21	Non-motor symptoms in a Flanders-Belgian population of 215 Parkinson's disease patients as assessed by the Non-Motor Symptoms Questionnaire. <i>American Journal of Neurodegenerative Disease</i> , 2012 , 1, 160-7	2.5	21
20	Large-scale assessment of polyglutamine repeat expansions in Parkinson disease. <i>Neurology</i> , 2015 , 85, 1283-92	6.5	20
19	Mutations in glucocerebrosidase are a major genetic risk factor for Parkinson's disease and increase susceptibility to dementia in a Flanders-Belgian cohort. <i>Neuroscience Letters</i> , 2016 , 629, 160-164	3.3	19
18	Contribution of VPS35 genetic variability to LBD in the Flanders-Belgian population. <i>Neurobiology of Aging</i> , 2012 , 33, 1844.e11-3	5.6	18

17	Comprehensive genetic and mutation analysis of familial dementia with Lewy bodies linked to 2q35-q36. <i>Journal of Alzheimer's Disease</i> , 2010 , 20, 197-205	4.3	17
16	Impulse control disorders in Parkinson's disease: an overview from neurobiology to treatment. <i>Journal of Neurology</i> , 2015 , 262, 7-20	5.5	15
15	REM sleep without atonia and the relation with Lewy body disease. <i>Parkinsonism and Related Disorders</i> , 2019 , 67, 90-98	3.6	11
14	Alpha-synuclein repeat variants and survival in Parkinson's disease. <i>Movement Disorders</i> , 2014 , 29, 1053-7		11
13	Non-replication of association for six polymorphisms from meta-analysis of genome-wide association studies of Parkinson's disease: large-scale collaborative study. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010 , 153B, 220-8	3.5	10
12	Guanosine triphosphate cyclohydrolase 1 promoter deletion causes dopa-responsive dystonia. <i>Movement Disorders</i> , 2012 , 27, 1451-6	7	9
11	GIGYF2 has no major role in Parkinson genetic etiology in a Belgian population. <i>Neurobiology of Aging</i> , 2011 , 32, 308-12	5.6	8
10	Contribution of rare homozygous and compound heterozygous VPS13C missense mutations to dementia with Lewy bodies and Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2021 , 9, 25	7.3	7
9	Frequency and characteristic features of REM sleep without atonia. <i>Clinical Neurophysiology</i> , 2019 , 130, 1825-1832	4.3	6
8	Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study. <i>Neurobiology of Aging</i> , 2017 , 49, 217.e1-217.e4	5.6	5
7	Polysomnographic phenotype of isolated REM sleep without atonia. <i>Clinical Neurophysiology</i> , 2020 , 131, 2508-2515	4.3	5
6	Spectrum of Movement Disorders in 18p Deletion Syndrome. <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 70-73	2.2	4
5	Impulsive-Compulsive Behaviours in Belgian-Flemish Parkinson's Disease Patients: A Questionnaire-Based Study. <i>Parkinson's Disease</i> , 2019 , 2019, 7832487	2.6	1
4	REM sleep without atonia and nocturnal body position in prediagnostic Parkinson's disease. <i>Sleep Medicine</i> , 2021 , 84, 308-316	4.6	1
3	Cerebellar ataxia in progressive supranuclear palsy: a clinico-pathological case report. <i>Acta Neurologica Belgica</i> , 2021 , 121, 599-602	1.5	
2	Reply to: The Spectrum of Movement Disorders in 18p Deletion Syndrome. <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 731-732	2.2	
1	Impaired bed mobility in prediagnostic and de novo Parkinson's disease.. <i>Parkinsonism and Related Disorders</i> , 2022 , 98, 47-52	3.6	